Diversified large cap med-tech Boston Scientific (NYSE: BSX )
has made meaningful progress in cleaning up its act, and the Street
has returned to the stock in force, pushing the stock up almost 70% over
the past year and over 100% over the past two years. That sort of
performance has left rivals like Medtronic (NYSE: MDT ) , Abbott Labs (NYSE: ABT ) , and St. Jude Medical (NYSE: STJ )
well in the dust, but now it's time to deliver. Can Boston Scientific
actually produce the growth and margin improvements that have
underpinned so much of this optimism?
Read the full article here:
Boston Scientific Corporation Needs Growth And Execution
No comments:
Post a Comment